"Our goal is helping investors grow their capital and income base from which to derive cash for their current and future needs," notes dividend expert Kelley Wright.

The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation. Our Timely Ten list represents our current top ideas.

"I've put together a retirement blue print that will allow anyone who is 20 years old or younger to retire a multi-millionaire," says Steve Christ.

The editor of The Wealth Advisory explains, "This diversified portfolio, contains a transport, a utility, a tech company, a health care giant, and a defense contractor, all of which pay nice steady dividends with room for growth.

"All you need to start is $15,000 initial investment to go along with an additional $100 bucks a week in total contributions divided among the five stocks.

"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.

The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.

"It seems plausible to expect the index to return about 13% in the coming year; not exactly a runaway bull, but a bright enough prospect to keep us in the game," says blue chip expert Richard Band.

The editor of Profitable Investing explains, "Here are three growth-and-income names that I deem suitable for virtually all investors of any age: Abbott Laboratories (ABT), Sysco (SYY) and Time Warner (TWX).

"Whether you're three years or 33 years from retirement, now is a good time to stock up on this trio of growth and income recommendations.

"Because major U.S. pharmaceutical companies face patent expirations on blockbuster drugs, consensus earnings expectations for the group are modest," says Richard Moroney.

The editor of Dow Theory Forecasts explains, "One exception is Abbott Laboratories (ABT); Wall Street expects to increase earnings at a 10% annual rate over the next five years.

"Yet the market appears to discount that outlook, and the stock's price/earnings-to-growth ratio (PEG) of 1.2 is well below its peers.

Analyst Upgrades

• Qualcomm (QCOM) was upgraded to outperform from neutral at Credit Suisse.
• JPMorgan upgraded Allegheny Tech (ATI) to overweight from neutral.
• NetApp (NTAP) was upgraded to buy from hold at Canaccord.
• Estee Lauder (EL) was upgraded to perform from underperform at Oppenheimer.
• Citigroup upgraded Suntech (STP) to hold from sell.

"Benjamin Graham has been recognized for decades as the father of value investing; Warren Buffett is known as the Oracle of Omaha for his superior investing skills," asserts J. Royden Ward, adding, "For this report, we combine Warren Buffett's and Ben Graham's criteria for choosing stocks.

The advisor reviews Abbott Laboratories (ABT), Coach (COH), Intel (INTC), Mastercard (MA), Microsoft (MSFT) and Tupperware Brands (TUP).

"We believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation," says dividend specialist Kelley Wright.

The editor of Investment Quality Trends explains, "Here we look at three blue chip stocks that have earned our top designation for outstanding dividend growth: IBM (IBM), Automated Data Processing (ADP) and Abbott Laboratories (ABT).

Analyst Upgrades

• Auriga upgraded Cisco (CSCO) to buy from hold, citing the company's improving strategic position in data centers.
• Blue Nile (NILE) was raised to buy from hold by Citigroup due to the recent pullback in shares.
• DuPont Fabros (DFT) was upgraded to buy from neutral at UBS, which said that said fundamentals in the data center space have been improving.
• Baird upgraded Sterling Bancshares (SBIB) to neutral from underperform based on valuation.
• Goldman Sachs upgraded Bristol-Myers (BMY) to buy from neutral.
• Amazon.com (AMZN) was raised to conviction buy from buy by Goldman.
• Jefferies upgraded Celgene (CELG) to buy from hold.

Analyst Upgrades

• FBR Capital upgraded Transocean (RIG) to outperform from market perform as it believes congressional hearings and reports indicate the company's blowout preventer at the Deepwater Horizon likely worked properly. The firm has an $87 price target for shares.
• Auriga upgraded First Solar (FSLR) to buy from hold as it believes the recent sell-off in shares as created an attractive entry point. Despite upgrading, the firm lowered its target for shares to $138 from $147.
• Soleil upgraded Priceline.com (PCLN) to buy from hold, citing a favorable risk-reward profile. Despite the upgrade, the firm lowered its target for shares to $230 from $250.
• Blackrock (BLK) was upgraded to conviction buy from buy at Goldman.
• Abbott (ABT) was upgraded to hold from sell at Citigroup.
• Exxon Mobil (XOM) was upgraded to outperform from sector perform at RBC Capital.

Analyst Upgrades

• Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
• JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
• Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
• Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
• Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
• Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.